Compounds and methods for treating aberrant adrenocortical cell disorders
Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and/or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethyl amino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient.
1. A method for treating a patient diagnosed as having 21-hydroxylase deficient congenital adrenal hyperplasia comprising administering to the patient a therapeutically effective amount of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride (ATR-101), wherein ATR-101 is administered orally one, two, three or four time daily to the patient.